Contact

Investors in biomarker development companies


,
Integral service around a transaction
BY : Diego GutiérrezJuly Fri, 2014
mortality--644x362The use of genetically-derived biomarkers is becoming a fundamental practice in hospitals because of their cost-effectiveness. Since 2005, 95 investors have invested in companies developing biomarkers, raising a total of $1,911M. The average amount invested by each investor is $22M, although there are large differences between investors. Some investors have invested more than $100M, while others have invested less than $150,000. 

venture capital

Investor profile

The characteristics of the investors vary widely. Thus, we find investors dedicated solely to the biotechnology sector such as Biotech Turnaround Fund y DeNovo or multi-sectoral funds such as Jafco Ventureswhich invests in technology-driven start-ups. In addition, there are investors who have only participated in one round of funding related to biomarkers, and investors who have carried out several.

Most active investors by number of rounds in which they have participated.

The most active investors are Mohr Davidow Ventures y Fisk VenturesThe total number of investments made is 5 each.

Mohr Davison, is a firm of venture capital  with more than 30 years of experience, focused on early stage technology companies. This fund has participated in more than 179 companies. In the field of biomarkers, it has allocated $76M with a round of 14M and 2 rounds in On-Q-ity y Tethys BioScience.

Fisk Venturesbetween 2006 and 2013, it has raised 5 rounds of funding in Singulexwhich develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. The total amount invested in the company is $77M.

Investors who have invested the most in the sector

If we take into account the amount invested by inverterthe firm at the top of the list is Viking Global InvestorsThis April 2014, this international firm, with offices in London, Hong Kong, New York and Greenwich, has carried out an financing round of $105M in Adaptive Biotechnologieswhich provides research and diagnostic tools for scientists and clinicians working in the field of genomic immunology.

Second place, with a investment of $99M is occupied by Domain AssociatesThe firm is an American venture capital firm focused solely on the biotechnology sector. This firm has invested in 2 companies related to biomarkers. Astute Medicalwhich develops activities for the identification and validation of protein biomarkers that can serve as a basis for new diagnostic tests, and Sera Prognostics, which develops blood tests to predict problems in pregnancy.

Other posts that may interest you

Caixa Capital Risc launches a new fund in the Biotech sector

Latest investments in "disease diagnostics

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu